Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 13/20 | 0.41 |
| ▸ | PPARG | P37231 | 2/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.39 |
| ▸ | GPR142 | Q7Z601 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pivalamide SCHEMBL5791007 | 0.96 | BRAF (0.39) | BRAFPPARGHDAC1HDAC8HDAC6 | |
| SCHEMBL5791013 | 0.95 | BRAF (0.39) | BRAFPPARGHDAC1HDAC8HDAC6 | |
| SCHEMBL1379069 | 0.89 | BRAF (0.39) | BRAFHDAC1HDAC8HDAC6GPR142 | |
| SCHEMBL4508137 | 0.85 | MEN1 (0.50) | BRAFPPARGHDAC1HDAC8HDAC6 | |
| SCHEMBL4463265 | 0.85 | BRAF (0.41) | BRAFPPARGPPARANR1H4GPR142 | |
| SCHEMBL1414199 | 0.85 | BRAF (0.41) | BRAFPPARGPPARANR1H4GPR142 | |
| SCHEMBL4473152 | 0.83 | BRAF (0.44) | BRAFGPR142 | |
| SCHEMBL4478013 | 0.83 | BRAF (0.40) | BRAFNR1H4GPR142 | |
| SCHEMBL4470712 | 0.83 | GPR142 (0.42) | BRAFGPR142 | |
| SCHEMBL4471832 | 0.82 | ITK (0.45) | BRAFPPARGPPARANR1H4GPR142 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7511042-B2 | 1-[5-(5-tert-Butyl-2-methoxy-3-methylsulfamoyl-phenylcarbamoyl)-2-methyl-phenyl]-1H-1,2,3-triazole-4-carboxylic acid (2,2-dimethyl-propyl)-amide; small molecule cytokine inhibitor; optimized efficacy, pharmacokinetic; antiinflammatory agent, osteoarthritis, asthma, gastrointestinal, respiratory disorder | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-03-31 | — | — | US | claimed |
| EP-1692116-A1 | 1,2,3-TRIAZOLE AMIDE DERIVATIVES AS INHIBITORS OF CYTOKINE PRODUCTION | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2006-08-23 | — | — | EP | claimed |
| US-20050153972-A1 | 1-[5-(5-tert-Butyl-2-methoxy-3-methylsulfamoyl-phenylcarbamoyl)-2-methyl-phenyl]-1H-1,2,3-triazole-4-carboxylic acid (2,2-dimethyl-propyl)-amide; small molecule cytokine inhibitor; optimized efficacy, pharmacokinetic; antiinflammatory agent, osteoarthritis, asthma, gastrointestinal, respiratory disorder | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-07-14 | — | — | US | claimed |
| WO-2005056535-A1 | 1,2,3-TRIAZOLE AMIDE DERIVATIVES AS INHIBITORS OF CYTOKINE PRODUCTION | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-06-23 | — | — | WO | claimed |
| US-7511042-B2 | 1-[5-(5-tert-Butyl-2-methoxy-3-methylsulfamoyl-phenylcarbamoyl)-2-methyl-phenyl]-1H-1,2,3-triazole-4-carboxylic acid (2,2-dimethyl-propyl)-amide; small molecule cytokine inhibitor; optimized efficacy, pharmacokinetic; antiinflammatory agent, osteoarthritis, asthma, gastrointestinal, respiratory disorder | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-20050153972-A1 | 1-[5-(5-tert-Butyl-2-methoxy-3-methylsulfamoyl-phenylcarbamoyl)-2-methyl-phenyl]-1H-1,2,3-triazole-4-carboxylic acid (2,2-dimethyl-propyl)-amide; small molecule cytokine inhibitor; optimized efficacy, pharmacokinetic; antiinflammatory agent, osteoarthritis, asthma, gastrointestinal, respiratory disorder | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153972-A1 | 1-[5-(5-tert-Butyl-2-methoxy-3-methylsulfamoyl-phenylcarbamoyl)-2-methyl-phenyl]-1H-1,2,3-triazole-4-carboxylic acid (2,2-dimethyl-propyl)-amide; small molecule cytokine inhibitor; optimized efficacy, pharmacokinetic; antiinflammatory agent, osteoarthritis, asthma, gastrointestinal, respiratory disorder | IL1A, IL1R1, IL1RN | BRAF 3675/4885PPARG 423/4885HDAC1 507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.